Abstract

Breast cancer, which accounts for over a quarter (24.2%) of all cancer cases and is the most frequently diagnosed cancer and the leading cause of cancer death in women globally, is expected to see 2.1 million new cases diagnosed in 2022. For determining the prognosis of a patient with breast cancer, there are numerous new adjunctive modalities available. The patient's prognosis can be learned a great deal from the flow cytometry. Important prognostic data can be obtained from DNA ploidy analysis, which can also aid in forecasting the behavior and aggressiveness of breast carcinomas. An aberrant DNA content condition called aneuploidy is frequently linked to more aggressive tumour characteristics, a higher likelihood of recurrence, and a worse prognosis in breast cancer patients. The present study was carried out to evaluate the impact of DNA ploidy on patient outcomes, such as disease-free survival, overall survival, and response to treatment. The prospective cohort study was conducted over a two-year period with the patient's previous agreement and with institutional ethical approval.

Description